gvax pancreatic cancer vaccine
Vaccineexperimental
Clinical trial activity
20 trials · 17 clinical orgs · 0 marketing orgs
Phase 1
10
Phase 2
14
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2001 (NCT00116467)
Timeline
Indications
Studied for
- Carcinoma, Renal Cell · Phase 1
- Colorectal Neoplasms · Phase 2
- Leukemia, Myeloid, Acute · Phase 2
- Leukemia, Myelomonocytic, Chronic · Phase 2
- Melanoma · Phase 1
- Myelodysplastic Syndromes · Phase 2
- Pancreatic Neoplasms · Phase 2
- Prostatic Neoplasms · Phase 1/Phase 2
- Sarcoma, Alveolar Soft Part · Phase 1
- Sarcoma, Clear Cell · Phase 1
Mechanism of action
- Tumor antigensImmunity, active
Tumor antigens immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- gvax
- gvax pancreatic cancer vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06782932 | Phase 1/Phase 2 (Phase 2) | May 27, 2025 | Agenus Inc., Johns Hopkins University, Lustgarten Foundation, Oncovir, Inc. |
| NCT03767582 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2019 | Bristol-Myers Squibb, Johns Hopkins University |
| NCT03153410 | Early Phase 1 (Phase 1) | Sep 1, 2017 | Eli Lilly, Johns Hopkins University, Merck |
| NCT03006302 | Phase 2 | Jun 1, 2017 | Johns Hopkins University |
| NCT02981524 | Phase 2 | May 1, 2017 | Johns Hopkins University |
| NCT02648282 | Phase 2 | Jul 1, 2016 | Johns Hopkins University, Merck |
| NCT02451982 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2016 | Johns Hopkins University |
| NCT02243371 | Phase 2 | Dec 1, 2014 | Aduro BioTech, American Association for Cancer Research, Bristol-Myers Squibb, Johns Hopkins University, Stand Up To Cancer |
| NCT02004262 | Phase 2 | Jan 1, 2014 | Aduro BioTech |
| NCT01966289 | Phase 1 | Dec 1, 2013 | Johns Hopkins University |
| NCT01952730 | Phase 1 | Jul 1, 2013 | Harvard University |
| NCT01773395 | Phase 2 | Jan 1, 2013 | Harvard University |
| NCT01696877 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2012 | Johns Hopkins University |
| NCT01417000 | Phase 2 | Sep 1, 2011 | Aduro BioTech, Johns Hopkins University |
| NCT00727441 | N/A | Jul 1, 2008 | Johns Hopkins University, National Cancer Institute (NCI) |
| NCT00122005 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2005 | Cell Genesys, Providence Health & Services |
| NCT00258687 | Phase 1 | Jan 1, 2005 | Harvard University |
| NCT01510288 | Phase 1 | Nov 1, 2004 | Cell Genesys, Free University of Amsterdam, Medarex, University of Amsterdam |
| NCT00084383 | Phase 2 | Jan 1, 2002 | Johns Hopkins University, National Cancer Institute (NCI) |
| NCT00116467 | Phase 2 | Mar 1, 2001 | Cell Genesys |
Showing 20 of 20 trials
Page 1 / 1
Organizations
Research & Development (17)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johns Hopkins University | Academic/Hospital | 13 | 12 | 3 | 2002 |
| Aduro BioTech | For profit | 3 | 2 | 1 | 2011 |
| Cell Genesys | For profit | 3 | 1 | 2 | 2001 |
| Harvard University | Academic/Hospital | 3 | 3 | 2 | 2005 |
| Bristol-Myers Squibb | For profit | 2 | 0 | 1 | 2014 |
| Merck | For profit | 2 | 0 | 2 | 2016 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 2002 |
| Agenus Inc. | For profit | 1 | 0 | 1 | 2025 |
| American Association for Cancer Research | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Eli Lilly | For profit | 1 | 0 | 1 | 2017 |
| Free University of Amsterdam | Academic/Hospital | 1 | 0 | 1 | 2004 |
| Lustgarten Foundation | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Medarex | For profit | 1 | 0 | 1 | 2004 |
| Oncovir, Inc. | For profit | 1 | 0 | 1 | 2025 |
| Providence Health & Services | Academic/Hospital | 1 | 1 | 1 | 2005 |
| Stand Up To Cancer | Academic/Hospital | 1 | 0 | 1 | 2014 |
| University of Amsterdam | Academic/Hospital | 1 | 1 | 1 | 2004 |
17 organizations
Page 1 / 1